Sunnua" Regional chemotherapy. delivered via the hepatic artery. may significantly increase tumour response rates in patients with colorectal liver metastases. However, survival is limited by extrahepatic disease progression. We have developed a novel therapeutic approach for patients with metastases confined to the liver. In order to achieve high local response rates and also inhibit extrahepatic progression. 5-fluorouracil (5-FU) was infused intra-arterially at a dose previously calculated to achieve both high-dose regional therapy and adequate systemic levels. To enhance efficacy further, 5-FU was combined with high-dose systemic folinic acid (FA). Thirty-one patients were evaluated in a phase II study. 5-FU (1.5 g m2) was infused via a surgically implanted hepatic artery catheter over a 24 h period: FA (total 400 mg m-2) was infused intravenously during the initial and final 2 h. Treatments were given weekly for cycles of 6 weeks' duration. To date, median duration of treatment is 6 months and the median follow-up period is 17 months. 1992a) we initiated a phase II study using high-dose IHA 5-FU so that 'spill-over' into the systemic circulation occurred. To enhance efficacy further. we adopted a schedule using prolonged infusions modulated by high-dose systemic folinic acid. Our aims were not only to maximise tumour response rates but also to delay extrahepatic progression in an attempt to prolong survival.
The outlook for patients with colorectal liver metastases is poor. Untreated. median survival is in the region of 3-6 months (Wood et al.. 1976 : Fortner et al.. 1984 . While hepatic resection offers a hope of cure for those with limited disease confined to one lobe, less than 5% of patients are suitable for such treatment. and in these 5 year survival is approximately 30% (Cady & Stone. 1991) . Thus the vast majority of patients remain incurable.
Until recently the results of systemic chemotherapy have been disappointing. 5-Fluorouracil (5-FU) and its analogue 5-fluoro-2-deoxyuridine (FUDR) remain the most active agents for colorectal metastases. but response rates to these alone are less than 20% (Kemeny & Seiter. 1991) . Most cytotoxic drugs have steep dose-response curves such that increased response rates are achieved with higher dose regimens. Attempts to increase systemic doses of 5-FU. however. have led to unacceptable toxicity.
Regional chemotherapy is an approach which can overcome this problem. Intrahepatic arterial (IHA) administration of cytotoxics has been shown to increase tumour response rates while at the same time systemic exposure and therefore toxicity are reduced (Kemeny et al., 1987; Pinedo. 1988) . FUDR. which is almost totally metabolised on first pass through the liver, has been widely used for the regional treatment of liver metastases. However, despite high response rates with this drug. it is apparent that survival is limited because patients develop extrahepatic metastases (O'Connell. 1992) .
Regional administration of 5-FU. which is incompletely extracted on first hepatic passage. may be an appropnrate alternative. Not only can this achieve high tumour drug levels. but also the systemic 'spill-over' could inhibit the growth of extrahepatic metastases. Furthermore, the therapeutic efficacy of 5-FU may be improved both by administering it as a prolonged infusion and by including biochemical modulators such as folinic acid (FA) in the regimen (Kerr. 1989; Lokich et al.. 1989) .
In this study we have combined these factors to develop a novel therapeutic approach. Based on pharmacokinetic and phase I studies (Goldberg et al.. 1990 hepatic tumour and catheterisation was 3 months (range 0-14 months). In patients with normal anatomy (n = 21), the catheters were inserted retrogradely into the gastroduodenal artery and positioned so that the catheter tip lay at its origin (Watkins et al., 1970) . In patients with variant anatomy, perfusion was achieved using a variety of techniques. These included ligation of aberrant vessels, the use of end-to-side saphenous vein grafts as conduits for catheter insertion (Goldberg et al., 1989) and retrograde cannulation of the splenic artery. Complete perfusion of the liver was confirmed in all patients by per-catheter injection of methylene blue dye. To prevent unwanted perfusion of other viscera any vessels supplying the stomach, duodenum or pancreas which took origin distal to the site of catheterisation were ligated. Cholecystectomy was performed to prevent chemical cholecystitis. The catheters were connected to access ports placed subcutaneously over the costal margin through a separate incision. One week post operatively the catheters were flushed with heparinised saline (2,000 units in 5 ml) using a Huber needle inserted under local anaesthetic. Following discharge, arrangements were made to commence treatment following a short period of convalescence (usually 2 weeks).
Chemotherapy was given according to the schedule previously determined by the phase I study (Anderson et al., 1992a) . Intra-arterial 5-FU (1.5 gm-) was administered as a weekly 24 h infusion with intravenous folinic acid (200 mg m2) given as infusions over the first 2 and last 2 h of the 24 h period. This dose was chosen in order to maximise the modulation of thymidylate synthetase inhibition by 5-FU (Anderson et al., 1992b) . Chemotherapy was commenced between 1 and 6 weeks (median 3 weeks) following insertion of catheter. All patients were given dexamethasone 8 mg i.v. at the start of each infusion as prophylaxis against nausea and vomiting. Additional antiemetics and antidiarrhoeal drugs were given if required. Oral ranitidine 150 mg b.d. was prescribed routinely to protect against peptic ulceration. Infusions were given weekly for 6 weeks followed by a 2 week rest prior to the start of the next treatment cycle. Dose reduction of 5-FU by 25% increments was performed for patients with symptoms of systemic toxicity not relieved by standard antiemetics or antidiarrhoeal agents.
Initially patients were admitted for treatment but latterly the infusions of 5-FU were administered using a portable pump (Walkmed 300, Medfusion, Duluth, USA). With this the patients attended hospital on an out-patient basis for commencement of their infusions and again, the following day, for the final folinic acid infusion and subsequent disconnection. (Table I) . Delayed responses occurred in four patients who initially had stable disease and subsequently had partial responses after a mean duration of 6 months (range 4-13 months). In addition, one patient who showed a partial response after the initial assessment converted to a complete response after 12 months of treatment. Thus 15 out of 31 patients (48%) responded overall. The patients who had complete responses remain disease free at 36 and 24 months. Three of the five patients who had previous intraarterial or systemic therapy had partial responses. Toxicity Systemic toxic effects occurred in 15 patients (Table II) . Nausea, vomiting and diarrhoea were the most frequent symptoms. Two patients developed oral mucositis. Toxic effects were generally mild, with no cases of grade 4 toxicity. Myelosuppression and hand/foot syndrome were not encountered. In the majority of patients symptoms were adequately controlled with standard antiemetics and antidiarrhoeal drugs. Four patients required dose reduction; three by 25% and one by 50%. Of these, two patients opted to discontinue treatment at 4 and 8 months, one with grade 2 and the other with grade 3 vomiting.
Local toxicity, attributable to arterial perfusion, was seen in four patients. Upper gastrointestinal haemorrhage from duodenal ulceration of duodenitis occurred in three patients, two of whom settled with conservative treatment. One patient required an emergency Polya gastrectomy. One patient had asymptomatic chemical hepatitis which resolved on cessation of treatment. Two patients developed liver abscesses. One grew a methicdllin-resistant Staphylococcus aureus which responded to treatment with vancomycin and percutaneous drainage, the other grew coliforms and responded to ciprofloxacin. One patient developed a retroperitoneal haematoma following catheter displacement, and bleeding from the injection port due to coring of the septum occurred in a further patient. To date, catheter occlusion has occurred in 15 patients with a median time to failure of 12 months (range 3-18 months).
Progression
To date, 24 patients have progressed. Predicted median time to progression is 8 months (Figure 1) . The liver was the site of initial progression in 10 (42%), whereas progression first occurred in extrahepatic sites in the remaining patients pulmonary and locoregional recurreni with equal frequency (Table III) (Widder et al., 1979) . At the first level selective ion was not delivery to the tumour-bearing organ is achieved. With he time of second-level targeting, drug is directed to tumour rather than to normal tissue within the organ. Third-level targeting enhances uptake of drug by malignant cells. As hepatic metastases derive their blood supply predominantly from the hepatic artery (Breedis & Young, 1954) , infusion of cytotoxics via the hepatic artery therefore achieves first-and, to a nic acid has degree, second-level targeting. With this approach higher ic treatment drug concentrations may be delivered to the tumour while rr, 1989 (Kemeny, 1992) . Despite this, the results of seven randomised studies comparing it with systemic therapy are less encouraging. Only one of these, a French consortium study, has shown significantly improved survival with regional administration (Rougier et al., 1992) extrahepatic metastases (O'Connell, 1992) . A logical approach, therefore, is to combine regional with adjuvant systemic treatment in order to inhibit extrahepatic progression. Safi et al. (1989) We have adopted an alternative approach. Because the first-pass hepatic extraction of 5-FU is between 19% and 54% (Ensminger et al., 1978) , intra-arterial administration of 5-FU is likely to produce not only high intrahepatic drug levels but also significant systemic levels as a result of unmetabolised drug spilling over from the liver into the systemic circulation. By combining this with folinic acid and using a prolonged infusional regimen, we aimed to maximise (Kemeny, 1992) . Systemic toxicity in this study was mild, with no grade 4 and only four cases of grade 3 toxicity. This is similar, in both spectrum and degree. to the toxicity encountered in studies of systemic 5-FU and folinic acid which utilised similar prolonged infusional schedules (De Gramont et al.. 1988 : Johnson et al.. 1991 . and therefore indicates that we were achieving equivalent therapeutic systemic drug levels.
Biliary sclerosis, commonly seen with regional FUDR infusion, was not seen, and only one patient had transient biochemical evidence of hepatitis. However, other local complications did occur. Despite prophylactic H,-blockers, upper gastrointestinal haemorrhage occurred in three patients, presumably as a result of misperfusion. Although this should be minimised by careful ligation of any vessels arising from the hepatic artery which supply stomach or duodenum, it is recognised that collaterals may develop (Kemeny et al., 1984) . Early investigation of dyspeptic symptoms by endoscopy is therefore mandatory.
Hepatic abscess formation was another serious complication. In the patient infected with Gram-negative bacilli this was associated with chronic suppuration at the subcutaneous port site, while a hospital-acquired staphylococcal infection occurred in the other. Despite this, both patients responded to parenteral antibiotic therapy (although one required additional percutaneous drainage). One is still alive 21 months post catheterisation while the other died at 20 months of progressive liver disease.
The majority of patients who progressed did so at extrahepatic sites in the first instance, indicating that control of local disease was superior to the inhibitory effect of the systemic component. However, the median time to progression of 8 months suggests that disease progression was delayed. The high response rate and relative lack of toxicity suggest that this regimen warrants further evaluation. A phase III study comparing systemic and regional 5-FU and folinic acid regimens is now planned.
